VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

Impact · against what's priced in

VolitionRx provides positive catalysts through a $7.3 million government-backed sepsis program and early lung cancer assay orders. The announcement of active licensing negotiations with 10 leading diagnostic firms suggests a shift toward a scalable revenue model, though the lack of finalized contracts keeps the impact speculative.

VNRX+0.60

No priced-in read yet